Search for a trial

Prophylactic infusion of CD4 positive donor lymphocytes early after T-cell depleted stem cell transplantation

In this phase II study, the toxicity and treatment effects of early donor derived CD4+ lymphocyte infusion, three months after SCT, will be evaluated

A Phase 1/2 study of the combination of pixantrone, etoposide, bendamustine and, in CD-20 positive tumors, rituximab in patients with relapsed aggressive non-Hodgkin lymphomas of B- or T-cell phenotype - The P[R]EBEN study

Primary Objectives- Determine the MTD of pixantrone, rituximab (only in CD20 positive tumors), etoposide, and bendamustine in *fit' patients with rel aNHL of B- or T-cell phenotype.- Evaluate the ORR and PFS using the combination of pixantrone…

A PHASE 2, SINGLE-ARM, MULTI-COHORT, MULTI-CENTER TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF JCAR017 IN ADULT SUBJECTS WITH AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA

Primary ObjectivesCohorts 1, 2, 3, 4, and 5• Determine the efficacy, defined as overall response rate (ORR), of JCAR017 in subjects with aggressive B-cell non-Hodgkin lymphomaCohort 7• Evaluate the safety of JCAR017 treatment in subjects intended to…

LONG-TERM FOLLOW-UP PROTOCOL FOR SUBJECTS TREATED WITH GENE-MODIFIED T CELLS

This study has been transitioned to CTIS with ID 2023-504201-36-00 check the CTIS register for the current data. Per Health Authority guidelines for gene therapy medicinal products that utilize integrating vectors (eg, lentiviral vectors), long-term…

A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL) (ZUMA-1)

The primary objective of Phase 1 study is to evaluate the safety of axicabtagene ciloleucel regimens.The primary objective of Phase 2 pivotal study is to evaluate the efficacy of axicabtagene ciloleucel, as measured by objective response rate (ORR)…

Randomized controlled trial on the effect of vitamin C supplementation in autologous stem cell transplantations

The aim of this study is to examine the effect of vitamin C supplementation on immune recovery in patients with autologous stem cell transplantation. The aim of the run-in phase of the study is to examine the effect of intravenous vitamin C…

A phase I/II study of lutetium (177Lu)-lilotomab satetraxetan (Betalutin®) antibody-radionuclide-conjugate for treatment of relapsed non-Hodgkin lymphoma.

PART B (FL phase IIb *PARADIGME*):Primary objective:Randomised section of Part B- To evaluate the efficacy of the *40/15* dose regimen (40 mg lilotomab / 15 MBq/kg Betalutin) compared with *100/20* dose regimen (100 mg/m2 lilotomab/ 20 MBq/kg…

A Phase 1/2, open label, multicenter study to assess the safety and tolerability of durvalumab (anti-PD-L1 antibody) as monotherapy and in combination therapy in subjects with lymphoma or chronic lymphocytic leukemia. (MEDI4736-NHL-001). The *FUSION NHL 001* Study.

PRIMARY: Dose finding part (Phase 1):To assess the safety and tolerability of durvalumab when given in combination with lenalidomide and rituximab; ibrutinib; or bendamustine and rituximab to determine the recommended Phase 2 doses (RP2Ds) of each…

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

This study has been transitioned to CTIS with ID 2023-506641-35-00 check the CTIS register for the current data. The primary objective is to evaluate the efficacy of KTE-X19, as measured by objective response rate (ORR), in subjects with r/r MCL.…

REmote iSchemic condItioning in Lymphoma PatIents REceiving ANthraCyclinEs (RESILIENCE)

- to reduce the prevalence of Heart Failure (HF) in cancer survivors- to improve screening strategies for early diagnosis of anthracycline-induced cardiotoxicity (AIC)Also the following objectives:- to identify early cardiotoxicity markers- to…